Hutchmed (China) announced the sale of a non-core joint venture for 0.608 billion USD.

Hutchmed (China) continues to fulfill the Global Strategy proposed in November 2022, driving value creation, adjusting product pipeline priorities, and bringing Innovative Drugs to Global patients. The proceeds from the sale of Assets will be used to further advance the company's product pipeline and core Innovative Drug Business. Key R&D investments include a proprietary antibody-drug conjugate platform, with the first candidates expected to enter clinical trials in the second half of 2025. Hong Kong, Shanghai, and Florham Park, New Jersey, January 1, 2025 /PRNewswire/ -- Hutchmed (China) has.

PR NewswireJan 1 09:42 ET

Hutchmed to Sell 45% Stake in JV for $608 Million

MT NewswiresJan 1 08:00 ET

HUTCHMED to Divest 45% Stake in JV With Shanghai Pharma

Seeking AlphaJan 1 07:45 ET

Hutchmed (China) (00013) subsidiary intends to sell a total of 45% equity in Shanghai Hutchmed.

Hutchmed (China) (00013) announced that on December 31, 2024, the seller Shanghai Hutchmed Investment (Xiang...

Zhitong FinanceJan 1 06:11 ET

HUTCHMED Sells Major Stake to Focus on Core Business

TipRanksJan 1 06:07 ET

Express News | HUTCHMED- Entered Two Agreements to Divest 45% Equity Interest in Shanghai Hutchison Pharmaceuticals to Gp Health Service Capital, Shanghai Pharmaceuticals Holding

ReutersJan 1 05:58 ET